ClinicalTrials.gg
RecruitingNCT07727512Updated Aug 21, 2026

PCOS and Brain Health

An observational study in PCOS, sponsored by University of Wisconsin, Madison. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by University of Wisconsin, Madison · Observational

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
45
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 183 studies in Polycystic Ovary Syndrome with a site in United States — 32 open to participants now, 42 under way, 1 of them phase 3. Polycystic Ovary Syndrome · United States.

Planned enrollment
22nd of 35
45 · median 65
Started
2026
with 5 others
Observational
37 of 183
8 open now
Primary completion
2028-08
later than 38 of 41 live
Registered
180th of 183
by date

Among the 183 studies in Polycystic Ovary Syndrome with a site in United States, this one is the 22nd largest by planned enrollment of the 35 observational ones that give a count, is one of 6 that started in 2026, is one of 37 observational ones, reaches primary completion later than 38 of the 41 other live ones, and was the 180th registered.

Polycystic Ovary Syndrome

959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

32 of the 183 studies in Polycystic Ovary Syndrome with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 183 studies in Polycystic Ovary Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine how polycystic ovary syndrome (PCOS) impacts overall brain health, such as cerebral blood flow (CBF), brain structure and connectivity, and cognitive performance. 45 reproductive aged (18-45 years) individuals with ovaries, with and without PCOS, will be enrolled to complete brain structure and CBF scans via magnetic resonance imaging (MRI) over 2 testing visits and can expect to be on study for approximately 5 hours over a 1 to 3 month period.

Read the detailed description

Aim 1: To determine whether individuals with PCOS exhibit reduced CBF at global, lobe and regional brain levels.

Aim 2: To assess whether individuals with PCOS have alterations in brain structure including grey and white volume, cortical thickness, or connectivity compared to controls.

Aim 3: To evaluate whether individuals with PCOS demonstrate impairments in cognitive performance, including verbal fluency, memory, and processing speed, relative to controls.

Aim 4: To characterize systemic immune cell states, circulating inflammatory and metabolic profiles, and epigenomic regulatory landscapes in peripheral blood of individuals with and without PCOS, and to evaluate whether these multiomic signatures are associated with CBF, brain structure, connectivity, and cognitive performance.

03

Conditions studied

  • PCOS

Keywords

  • brain health
  • cerebral blood flow
  • polycystic ovarian syndrome
  • brain structure
  • cognition
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Reproductive-aged individuals with ovaries, with and without PCOS

Eligibility criteria

Inclusion Criteria (Participants with PCOS):

  • Rotterdam criteria demonstrating two out of the three criteria. These are:

    1. Presence of clinical hyperandrogenism or biochemical hyperandrogenism
    2. A history of irregular menstrual cycles
    3. Presence of polycystic ovarian morphology on ultrasound

Inclusion Criteria (Healthy Controls):

  • Regular menstrual cycles (not meeting criteria for irregular cycles above)
  • No diagnosis of PCOS
  • Controls may have isolated hirsutism or polycystic ovaries on ultrasound as long as they do not meet Rotterdam criteria for PCOS

Exclusion Criteria:

  • Current pregnancy
  • Preexisting diagnosis of type 1 diabetes
  • Severe obesity ( (BMI) greater than 45kg/m2)
  • Preexisting diagnosis of hypertension requiring antihypertensive medication or blood pressure of greater than 160/100 on two separate occasions during clinical care
  • History of neurologic disease or stroke
  • History of myocardial infarction or deep venous thrombosis
  • Endometriosis confirmed by prior laparoscopy
  • conditions including lupus, multiple sclerosis, and active
  • Immuno-modulating medications
  • Conditions incompatible with MRI scanning, including but not limited to

    • Certain implanted metal devices or foreign bodies
    • Severe claustrophobia
  • Participants will be excluded if they have taken hormonal or fertility medication in the last month
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
45 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Participants with PCOS

    N=30 participants recruited

    Device: MRI Visit · Other: Laboratory Visit

  • Healthy Controls

    N=15 age and BMI-matched participants recruited

    Device: MRI Visit · Other: Laboratory Visit

Interventions

  • DeviceMRI Visit

    MRI visit will take approximately 1.5 hour (55-60 minutes in MRI) and will involve structural scans of the brain, and scans at rest and while performing cognitive tasks.

    Also known as: magnetic resonance imaging

  • OtherLaboratory Visit

    DEXA scan for obtaining body composition, NIH toolbox to assess cognitive test, and optional graded exercise test (GXT).

06

What researchers measure

Primary outcomes

  1. Cerebral Blood Flow (CBF) at rest

    Arterial Spin Labeling (ASL) color atlases and 4D Flow MRI will be used to measure CBF at rest. CBF will be measured in each of six brain regions: temporal, parietal, frontal, occipital, subcortical, and brainstem.

    Time frame: data collected during a 2-hour MRI visit (anytime up to 3 months on study)

  2. Circulating Sex Hormone Levels

    Time frame: data collected during a 2-hour MRI visit (anytime up to 3 months on study)

Secondary outcomes

  1. Body composition via DEXA scan

    Percent body fat and lean mass to be measured via Dual-Energy X-ray Absorptiometry (DEXA) scan.

    Time frame: data collected during a 2-hour lab visit (anytime up to 3 months on study)

  2. NIH Toolbox: Dimensional Change Card Sort Test

    NIH Toolbox to assess neurocognitive function. The Dimensional Change Card Sort Test measures accuracy: the number of accurate responses, up to a maximum of 40.

    Time frame: data collected during a 2-hour lab visit (anytime up to 3 months on study)

  3. NIH Toolbox: Pattern Comparison Processing Speed Test

    NIH Toolbox to assess neurocognitive function. The Pattern Comparison Processing Speed Test measures how many correct responses the participant has within 90 seconds. There is a maximum of 130 items.

    Time frame: data collected during a 2-hour lab visit (anytime up to 3 months on study)

  4. NIH Toolbox: Flanker Inhibitory Control and Attention

    NIH Toolbox to assess neurocognitive function. The Flanker test is a measure of executive function and is scored using a T-score where 100 is the average, higher scores indicate better performance.

    Time frame: data collected during a 2-hour lab visit (anytime up to 3 months on study)

  5. Cardiorespiratory fitness (VO2max) [Optional]

    Time frame: data collected during a 2-hour lab visit (anytime up to 3 months on study)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Aug 2028, 24 months after the start.

Of 71 non-industry observational studies under Polycystic Ovary Syndrome, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 47. This study's planned 24 months is above that.

Counting every sponsor, half of 74 studies reached it within 14 months; a quarter within 6 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2026
First posted
Jul 27, 2026
StartActual
Aug 7, 2026
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2028
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07727512
Responsible party
Sponsor
First posted
Jul 27, 2026
Start date
Aug 7, 2026
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Aug 21, 2026

Study contacts

Sharon Blohowiak
Contact
sblohowiak@wisc.edu
(608) 262-5977
Laura Cooney, MD
principal investigator · University of Wisconsin, Madison

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion